Nyxoah S.A. (NYXH)
NASDAQ: NYXH · Real-Time Price · USD
6.95
-0.70 (-9.15%)
Mar 31, 2025, 2:24 PM EDT - Market open
Company Description
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.
The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A.
| Country | Belgium |
| Founded | 2009 |
| IPO Date | Jul 2, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 184 |
| CEO | Olivier Taelman |
Contact Details
Address: Rue Edouard Belin 12 Mont-Saint-Guibert, 1435 Belgium | |
| Phone | 32 10 22 23 55 |
| Website | nyxoah.com |
Stock Details
| Ticker Symbol | NYXH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $30.00 |
| CIK Code | 0001857190 |
| ISIN Number | BE0974358906 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Olivier Taelman | Chief Executive Officer and Executive Director |
| Robert Taub MBA | Co-Founder and Chairman |
| Remi Renard | Chief of Staff |
| Jeyakumar Subbaroyan | Chief Clinical Officer |
| Francis S. Kim | Chief Regulatory and Quality Officer |
| Dr. Maurits S. Boon | Chief Medical Officer |
| Scott Holstine | Chief Commercial Officer |
| Doug Heidrich | Senior Vice President of Sales - US |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2025 | 6-K | Report of foreign issuer |
| Mar 20, 2025 | F-3 | Filing |
| Mar 20, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 20, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 13, 2025 | 6-K | Report of foreign issuer |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Jan 2, 2025 | 6-K | Report of foreign issuer |
| Dec 13, 2024 | 6-K | Report of foreign issuer |
| Dec 2, 2024 | 6-K | Report of foreign issuer |
| Nov 20, 2024 | 6-K | Report of foreign issuer |